Attached files
Exhibit
32.1
CERTIFICATION
PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF
2002
(18
U.S.C. SECTION 1350)
In
connection with the Quarterly Report of Aeolus Pharmaceuticals,
Inc. (the “Company”) on Form 10-Q for the period ended
December 31, 2016, as filed with the Securities and Exchange
Commission on the date hereof (the “Report”), the
undersigned, John L. McManus, Principal Executive Officer of the
Company, and David Cavalier, Principal Financial and Accounting
Officer of the Company, each certify pursuant to 18 U.S.C. Section
1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act
of 2002, that, to the best of his knowledge:
1.
The Report fully
complies with the requirements of Section 13(a) or 15(d) of the
Securities Exchange Act of 1934; and
2.
The information
contained in the Report fairly presents, in all material respects,
the financial condition and results of operations of the
Company.
Date:
February 17, 2017
/s/ John L.
McManus
John L.
McManus
President and Chief
Executive Officer
(Principal
Executive Officer)
Date:
February 17, 2017
/s/ David
Cavalier
David
Cavalier
Chairman, Chief
Financial Officer and Secretary
(Principal
Financial and Accounting Officer)
THIS
CERTIFICATION “ACCOMPANIES” THE QUARTERLY REPORT, IS
NOT DEEMED FILED WITH THE SEC AND IS NOT TO BE INCORPORATED BY
REFERENCE INTO ANY FILING OF THE COMPANY UNDER THE SECURITIES ACT
OF 1933, AS AMENDED, OR THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED (WHETHER MADE BEFORE OR AFTER THE DATE OF THE QUARTERLY
REPORT), IRRESPECTIVE OF ANY GENERAL INCORPORATION LANGUAGE
CONTAINED IN SUCH FILING. A SIGNED ORIGINAL OF THIS CERTIFICATION
HAS BEEN PROVIDED TO THE COMPANY AND WILL BE RETAINED BY THE
COMPANY AND FURNISHED TO THE SECURITIES AND EXCHANGE COMMISSION OR
ITS STAFF UPON REQUEST.